|
|
Strategic Analysis of the World Plant Molecular Farming MarketPublished by: Frost & Sullivan Published: Dec. 21, 2004 Table of Contents1. Strategic Analysis of the World Plant Molecular Farming Market 1. Overview 1. Overview 2. Research Scope & Methodology 1. Research Scope & Methodology 3. Introduction & Background 1. Introduction & Background 4. World Industry Dynamics 1. World Industry Dynamics 2. Influences on the Plant Molecular Farming Market 3. Global Distribution of Transgenic Crops 4. Key Market Engineering Measurements - World Biopharmaceuticals Market 5. Total Market Revenue Forecasts - World Biopharmaceuticals Market 5. World Market Dynamics 1. World Market Dynamics 2. Key Challenges for the World Plant Molecular Farming Market 3. Key Market Trends 4. Current World Market Status 5. Market Drivers 6. Market Restraints 7. Geographical World Industry Distribution 8. Research Trends - Products in Development 9. Worldwide Industry Participants 6. North American Market Dynamics 1. North American Market Dynamics 2. Current Industry Status - North America 3. Forecast Assumptions 4. Key Market Engineering Measurements 5. Total Market Revenue Forecasts 6. Market Analysis 7. Product Timeline - North American Competitors 8. Competitive Profiles 7. European Market Dynamics 1. European Market Dynamics 2. Current Industry Status - Europe 3. Key Market Engineering Measurements 4. Total Market Revenue Forecasts 5. Market Analysis 6. Product Timeline - European Competitors 7. Competitive Profiles 8. Rest of World Market Dynamics 1. Rest of World Market Dynamics 2. Key Participants: Rest of World 9. Strategic Analysis & Reccomendations 1. Strategic Analysis & Recommendations 2. Key Challenges and Strategic Proposals 3. Strategic Anticipation 4. Market Maturation Process 5. Market Penetration Strategy 6. Competitive Framework 7. Potential Threats 8. Meeting the Challenge 10. Frost & Sullivan Awards 1. Frost & Sullivan Awards 2. Frost & Sullivan Awards Description 3. Growth Strategy Leadership Award 4. Technology Leadership Award 5. Entrepreneurial Company Award 6. Market Leadership Award 7. Product Differentiation Innovation Award 11. Decision Support Databases 1. Decision Support Databases 2. Number of Biotechnology Companies - Western Europe and North America (1999-2006) 3. Number of Biotechnology European Patents Filed (1996 - 2000) 4. Governmental R&D Investment in Biotechnology (1996-2000) 5. Pharmaceutical R&D Expenditure 1999 - 2006 12. Frost & Sullivan 1. Frost & Sullivan 2. Healthcare Team 3. Our Capabilities AbstractRecombinant Plants to Alleviate Production Issues in Plant Molecular FarmingThe demand for biopharmaceuticals is increasing, but little progress is being made to reduce production costs or increase manufacturing capacity. There are insufficient facilities to cope with the demand for products and new leads in drug discovery. The use of recombinant plants as factories to express recombinant proteins has the potential to alleviate this bottleneck. The production platforms and technologies that enable this are now in place and the onus is squarely on product development to commercially introduce therapeutics, and several companies have attracted venture capital sponsorship, and they are likely to be in a position to achieve this within the next two years. This strategic analysis service provides an overview of and outlook for the world plant molecular farming (biofarming) market. The study provides information on the world industry dynamics with a particular focus on North America and Europe as major centers of activity in this sector. It also offers strategic recommendations that enable companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investment. Transgenic Plants Have the Potential to Improve Biopharmaceutical Production Efficiency Biopharmaceutical manufacturers’ concerns about production capacity can be eased by investing in new manufacturing technologies and methods such as using transgenic plants as factories to produce biopharmaceuticals. "The cost of production can be significantly reduced by producing larger volumes, and eliminating the need for capital investment in fermentation systems," says the analyst of this research. Using microscopic plants such as lemna or moss in bioreactors have the potential to eliminate containment problems and improve turnover times by simplifying recombination procedures. Drug Discovery Market Governed by Regulatory Affairs and Public Perception Currently, there are no biopharmaceutical products manufactured using plant molecular farming in the market, with the first products anticipated to reach the market around 2005-06. However, the U.S. market could be worth $2.20 billion in 2011, as this emerging sector rapidly gathers pace as public perception and the regulatory climate improve. Growth is likely to occur fastest between 2008 and 2010 as more products enter the market and receive regulatory approval. "The gradual relaxation of the unofficial moratorium on transgenic crops in Europe is a good indication that the public and regulatory perception toward transgenic crops is improving, and this trend is expected to drive the market," notes the analyst.
|
|
|||
|
About MarketResearch.com
|
||||